ResearchDurvalumab Plus Chemotherapy in Patients With-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
ResearchVaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia
ResearchIPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
ResearchDerivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
ResearchOsimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
ResearchPre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
ResearchPaediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
ResearchMolecular Genetic Abnormalities in the Genome of Patients with Ph-Negative Myeloproliferative Neoplasia Affected by Ionizing Radiation as a Result of the Chornobyl Nuclear Accident
ResearchCopy Number Alterations and Copy-Neutral Loss of Heterozygosity in Ukrainian Patients with Primary Myelofibrosis
ResearchCopy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis
ResearchCharacteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident
ResearchNicotinamide N-methyltransferase expression decreases in iron overload, exacerbating toxicity in mouse hepatocytes